In Reply: Dr Shuldiner and colleagues criticize my assertion that physicians should require a prospective randomized trial before using CYP2C19 pharmacogenomics in clinical practice. Specifically, they state that such a conservative approach “may be denying patients access to potentially life-saving individualized alternative therapies.”
I could not more strongly disagree. For decades, women were treated with hormone therapy to prevent heart disease based on observational studies, only to find out that such treatments increase, rather than decrease, morbidity and mortality.1,2 Similarly, inappropriate use of surrogate end points has repeatedly promoted adoption of therapies that later proved ineffective or harmful. Examples include drugs to increase high-density lipoprotein cholesterol or reduce blood glucose such as rosiglitazone.3,4 Platelet reactivity testing represents another unvalidated surrogate end point and cannot be a substitute for studies that measure morbidity and mortality, which are the outcomes of importance to patients and physicians.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.